secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001683168-26-000398
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health releases corporate presentation highlighting late-stage pipeline in radiation damage and oncology
--------------------------------------------------------------------------------

- Company targeting multiple high-value inflection points expected within the next 18-24 months.
- Focus on competitively differentiated treatments for radiation damage, oncology, and immune system modification.
- Pipeline described as late-stage and highly de-risked; experienced management team in place.
- Corporate presentation furnished as Exhibit 99.1; no specific financial or clinical data disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826000398/0001683168-26-000398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826000398/tivic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-000398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer